key: cord-0761774-68vviche authors: Verma, Henu Kumar; Merchant, Neha; Verma, Manish Kumar; Kuru, Cansu İlke; Singh, Anand Narayan; Ulucan, Fulden; Verma, Poonam; Bhattacharya, Antaripa; Bhaskar, L.V.K.S. title: Current Updates on the European and WHO Registered Clinical Trials of Coronavirus Disease 2019 (COVID-19) date: 2020-07-24 journal: Biomed J DOI: 10.1016/j.bj.2020.07.008 sha: db31e84238eabbc0265532574c4a3196296ba6fc doc_id: 761774 cord_uid: 68vviche BACKGROUND: Coronavirus disease 2019 (COVID-19) is a major public health concern currently. To date, there are no approved antiviral drugs or vaccines against this transmissible disease. This report sheds light on available information for a better understanding of clinical trials and pharmacotherapy related to COVID-19. METHODS: MEDLINE, PubMed, EMBASE, Scopus databases, Web of Science, WHO, and EU clinical trial sites were used to perform comparative analysis. Information was collected on the use of therapeutic agents for human therapy in patients with COVID-19 up to May 2020. RESULTS: We have extracted data from 60 clinical trials. Amongst these trials, 34 were from the European Union database of clinical trials and 26 from the National Institute of health. The data selection procedure includes active, completion, and recruitment in progress status. Most of the clinical trials are ongoing and hence, there is a lack of precise results for the treatment. CONCLUSIONS: There is a lack of high-quality clinical evidence. The protocol to be developed requires large randomized clinical trials with a combination of available drugs and prospective therapies. We propose the usage of a large number of cases and different statistical analyses to conduct systematic clinical trials. This could provide comprehensive information about the clinical trial and potential therapeutic progress. COVID-19 is a pneumonia-like disease, which is caused by a novel coronavirus [1] . Coronavirus belongs to Orthocoronavirinae subfamily of the Coronaviridae family within the order Nidovirales. COVID-19 is the defining global health crisis that has spread over 205 countries including USA, Italy, Russia, Spain, Japan, Korea, Iran, and Germany [2, 3] . By the end of December 2019, a serious pneumonia like cluster of cases with unknown source expanded globally from Wuhan, China [4] . Various reports suggest that the novel coronavirus is 96.2% identical to a bat CoV RaTG13 [5, 6] . Evolutionary analysis of virus genome has suspected bat as a natural host of the virus origin that could have been transmitted from an unknown intermediate host to the humans [7] . The infection poses a significant risk to patients with COVID-19 due to the high frequency of pneumonia, fever, and dry cough.Additionally, patients suffer from the potential damage of vital organs, especially the lungs, heart, liver, and kidneys [8] [9] [10] . As per the latest reports from China, the mortality rate of COVID-19 disease is approximately 3-4% [11] . The latest data obtained on 30 June 2020 describes that COVID-19 has infected more than Ten million people worldwide. Amongst these cases, 5.6 million have been successfully treated and 5,08,422 has died. The number of infected people is increasing every day by one thousand worldwide. Recently, severity model based analysis has showed that the fatality ratio for China is 0·66%, on the Diamond Princess ship is 2.3%, and the large meta-analysis of 36 European countries showed the case fatality rate of COVID 19 range of 4% to 4.5% with an increasing profile with age [12] [13] [14] . Furthermore, in current scenario, India is ranked as the fourth highest country with positive cases and a case fatality rate of 1.9 to 3.6 % [15] . In the current situation, a second wave of coronavirus has hit the major cities of European countries including Sao Paulo and Rio de Janeiro, which is the centre for pandemic. Till date, more than 1.3 million positive cases have been identified in Brazil [16] . In Russia, more than 687,862 cases and 10,296 deaths due to COVID-19 infection has been reported [17] . In order to treat COVID-19, the only available treatment currently available is the retroviral therapy. Further, it was proven that convalescent plasma transfusion (CPT) is useful against COVID-19 [18, 19] . At this crucial moment, in-depth research is essential to treat and prevent the disease. Several researchers have promptly carried out clinical research aimed towards the diagnosis, treatment, and prevention of COVID-19 [20] . However, globally there is limited information available to analyze and summarize the registered clinical trials. The purpose of this review is to summaries existing COVID-19 clinical trial data that would aid in selecting the most appropriate COVID-19 treatment. Using various keywords related to COVID-19 including comorbidities, clinical characteristics, epidemiological, immunotherapy, vaccine, and SARS CoV-2 clinical trial data were obtained from different electronic databases. Some of these databases were European union clinical trials database, Clinical Trial Registry, Clinicatrial.gov, International Clinical Trials Registry Platform (WHO ICTRP), Chinese Biomedical Literature Database, and the Wanfang Database. Pubmed, the National Library of Medicine (NLM), and EMBASE database were also used to identify ongoing trials. All investigators have selected only the most appropriate and suitable studies. Inclusion criteria encompasses the following: (1) studies of COVID-19 patients' clinical trials (2) detailed protocol of clinical trials (3) data mining (4) the original design type (Interventional or observational) (5) reports that involved the treatment of COVID-19. The exclusion criteria includes the following: (1) studies having duplicate data and (2) vague theoretical research and unregistered clinical trials. Quality of clinical data and extracted data from the literature were assessed by rigorous information cross-check. Discrepancy between the investigators was resolved and the final decisions were decided without any conflicts. Relevant data was summarized in a narrative manner and the treatment strategy was grouped. Each table was categorized according to the drug usage. Results were classified based on the type of study, country, dose, duration of administration, an indication of medication, and the number of patients included in the study. (Table 1 and Table 2 ). Above all, most of the trials have cleared the ethical approval. Some of the case studies are still in the recruitment phase, whereas 20 trials have begun recruiting patients. Amongst them, only 4 trials are in active phase and in the next few days, patient recruitment will begin. 2 clinical trials are still incomplete. The leading intervention strategy of registered clinical trials consists of traditional Chinese medicine, western medicine, and conventional integrated treatment. Especially, the outcome of therapy includes treatment time, patient immunity, frequency of use of ventilation, mortality, number of complications, and virological detection indicators. Current duration of the medication is more than 10 days. Medicinal approaches include oral, injection, and inhalation. Two clinical trials include biological agents (product mRNA, blood stem cells, cord blood mononuclear cells, mesenchymal stem cell (MSC), recombinant cytokine gene-derived vector, and immunoglobulin (IgM, IgG). Since to 4000 candidates/trials and 8 observational studies, that included around 1000 to 3000000 candidates. Most of the trials are on-going; thus, the confirmation level and the clinical significance is limited ( Table 1 ). The alternative strategy to fight against COVID-19 is mainly based on boosting immune responses and to prevent the disease complications. This strategy improves patient immunity by predominating self-immune damage to the cytokine storm (modulating the post-infection immune response) and symptomatic treatment [23] . Although some Chinese herbs have shown both antiviral and high immune effects, current situations prove that the antiviral effect of western drugs is superior and tolerable in comparison to the traditional ayurvedic, Unani, or homeopathic medicines [24, 25] . The combination of Qingfeipaidutang and hydroxychloroquine phosphate might be a potential therapeutic strategy for the treatment and management of COVID-19 [26, 27] . Recently, an open-label, randomized clinical trial of standard medical treatment or colchicine (1.5-mg loading dose by 0.5 mg after 60 min and maintenance doses of 0.5 mg twice daily) in 105 patients showed that event-free survival time was 20.7 days in the colchicine group and 18.6 days in the control group and a significantly improved time to clinical deterioration [28] . Another multicenter, open-label randomized controlled trial in 160 patients with Shenhuang granule (50 g of Panax ginseng C. A. Mey, 40 g of Rheum palmatum L. stem, 30 g of Sargentodoxa cuneata stem, 30 g of Taraxacum mongolicum, 50 g of Aconiti Lateralis Radix Praeparata, and 6 g of Whitmania pigra Whitman) twice a day for 14 days is underway and the trail results are awaiting [29] . Still, there is a lack of high-grade substantiation evidence that demands further clinical clarification and verification. Several clinical researchers have used biological products for the treatment of COVID-19. In order to treat COVID-19 infection, Steroid-based therapy has been implemented and the result availability is limited for trials [13, 30] . The most commonly used drug is chloroquine (anti-malaria) and ribavirin with a broad-spectrum antiviral combination of Remdesivir and IFN-α2b. An interventional study based in Spain was registered at ClinicalTrials.gov on 1 April 2020 (ID: NCT04334928). Currently, this is the only clinical trial underway with Emtricitabine/tenofovir disoproxil / hydroxychloroquine against COVID-19 infection. Due to minimal interaction, the combination of baricitinib and lopinavir/ritonavir / remdeviate antivirals was used to treat the infection COVID-19 during the pandemic. The combination of baricitinib and above-mentioned drugs may reduce viral replication, infectivity, and aberrant host inflammatory response [31] . In most trials, inclusion and exclusion criteria has eliminated children under 18 Further; we must recognize the ancient history report of previous infectious diseases in order to implement novel conceptual health-related policies. Not applicable. All authors have read the manuscript and approved this submission. Not applicable. The Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center WHO Declares COVID-19 a Pandemic Covid-19: death rate is 0.66% and increases with age, study estimates Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) A pneumonia outbreak associated with a new coronavirus of probable bat origin Coronavirus: why a permanent ban on wildlife trade might not work in China Zoonotic origins of human coronaviruses The many estimates of the COVID-19 case fatality rate The Fuzzy Connection between SARS-CoV-2 Infection and Loss of Renal Function Coronavirus-nephropathy; renal involvement in COVID-19 Death in the era of the COVID-19 pandemic Estimates of the severity of coronavirus disease 2019: a model-based analysis Estimating the infection and case fatality ratio for COVID-19 using age-adjusted data from the outbreak on the Diamond Princess cruise ship Increase in COVID-19 cases and case-fatality and case-recovery rates in Europe: A cross-temporal meta-analysis Laxmi Kant Dwivedi, Suryakant Yadav, Sayeed Unisa.,. Case-Fatality Ratio and Recovery Rate of COVID-19: Scenario of Most Affected Countries and Indian States International Institute for Population Sciences Assessing the potential impact of COVID-19 in Brazil: Mobility, Morbidity and the burden on the Health Care System Convalescent plasma: new evidence for an old therapeutic tool? Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): current updates Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review Death in the era of the COVID-19 pandemic Covid-19: UK records first death, as world's cases exceed 100 000 COVID-19: Immunology and treatment options COVID-19: A promising cure for the global panic Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 Is traditional Chinese medicine useful in the treatment of COVID-19? Traditional Chinese medicine for COVID-19 treatment Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial Shenhuang granule in the treatment of severe coronavirus disease 2019 (COVID-19): study protocol for an open-label randomized controlled clinical trial Italian Society of P. NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators? COVID-19: combining antiviral and anti-inflammatory treatments We thank Deepak Kumar Verma, IIT Kharagpur, India for providing a factual review and assistance throughout our study and for their help in editing the manuscript. • Drugs currently recommended treating COVID-19 such as hydrochloride, interferon, andThalidomide plus can also be used with other combination.• More clinical studies are needed to confirm the use of antiviral corticosteroids, if they prove to be effective in human clinical studies All authors have declared that there are no conflicts of interest.